vs

Side-by-side financial comparison of NCS Multistage Holdings, Inc. (NCSM) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $50.6M, roughly 1.5× NCS Multistage Holdings, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 12.5%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $12.9M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 7.4%).

NCS Multistage Holdings, Inc. is a global oilfield services and energy technology provider specializing in engineered completion systems for onshore and offshore oil and gas production. It offers multistage fracturing tools that optimize well performance, serving major operators across North America, Latin America, the Middle East and Asia-Pacific, focusing on boosting operational efficiency and resource recovery for upstream energy clients.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

NCSM vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.5× larger
PBYI
$75.5M
$50.6M
NCSM
Growing faster (revenue YoY)
PBYI
PBYI
+15.2% gap
PBYI
27.7%
12.5%
NCSM
More free cash flow
PBYI
PBYI
$1.5M more FCF
PBYI
$14.4M
$12.9M
NCSM
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
7.4%
NCSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NCSM
NCSM
PBYI
PBYI
Revenue
$50.6M
$75.5M
Net Profit
$15.0M
Gross Margin
69.3%
Operating Margin
10.3%
22.7%
Net Margin
29.5%
Revenue YoY
12.5%
27.7%
Net Profit YoY
331.0%
EPS (diluted)
$5.43
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NCSM
NCSM
PBYI
PBYI
Q4 25
$50.6M
$75.5M
Q3 25
$46.5M
$54.5M
Q2 25
$36.5M
$52.4M
Q1 25
$50.0M
$46.0M
Q4 24
$45.0M
$59.1M
Q3 24
$44.0M
$80.5M
Q2 24
$29.7M
$47.1M
Q1 24
$43.9M
$43.8M
Net Profit
NCSM
NCSM
PBYI
PBYI
Q4 25
$15.0M
Q3 25
$3.8M
$8.8M
Q2 25
$924.0K
$5.9M
Q1 25
$4.1M
$3.0M
Q4 24
$3.5M
Q3 24
$4.1M
$20.3M
Q2 24
$-3.1M
$-4.5M
Q1 24
$2.1M
$-4.8M
Gross Margin
NCSM
NCSM
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
NCSM
NCSM
PBYI
PBYI
Q4 25
10.3%
22.7%
Q3 25
6.6%
17.6%
Q2 25
-5.6%
12.7%
Q1 25
8.6%
8.7%
Q4 24
6.5%
22.6%
Q3 24
6.9%
27.4%
Q2 24
-14.0%
-4.6%
Q1 24
5.7%
-5.3%
Net Margin
NCSM
NCSM
PBYI
PBYI
Q4 25
29.5%
Q3 25
8.2%
16.2%
Q2 25
2.5%
11.2%
Q1 25
8.1%
6.5%
Q4 24
7.7%
Q3 24
9.4%
25.2%
Q2 24
-10.4%
-9.6%
Q1 24
4.7%
-11.0%
EPS (diluted)
NCSM
NCSM
PBYI
PBYI
Q4 25
$5.43
$0.26
Q3 25
$1.37
$0.17
Q2 25
$0.34
$0.12
Q1 25
$1.51
$0.06
Q4 24
$1.34
$0.40
Q3 24
$1.60
$0.41
Q2 24
$-1.21
$-0.09
Q1 24
$0.82
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NCSM
NCSM
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$36.7M
$97.5M
Total DebtLower is stronger
$5.3M
$22.7M
Stockholders' EquityBook value
$126.2M
$130.3M
Total Assets
$181.2M
$216.3M
Debt / EquityLower = less leverage
0.04×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NCSM
NCSM
PBYI
PBYI
Q4 25
$36.7M
$97.5M
Q3 25
$25.3M
$94.4M
Q2 25
$25.4M
$96.0M
Q1 25
$23.0M
$93.2M
Q4 24
$25.9M
$101.0M
Q3 24
$15.3M
$96.7M
Q2 24
$18.6M
$96.8M
Q1 24
$14.0M
$107.2M
Total Debt
NCSM
NCSM
PBYI
PBYI
Q4 25
$5.3M
$22.7M
Q3 25
$5.1M
$34.0M
Q2 25
$5.5M
$45.3M
Q1 25
$5.4M
$56.7M
Q4 24
$6.0M
$68.0M
Q3 24
$6.5M
$79.3M
Q2 24
$6.8M
$90.7M
Q1 24
$6.4M
$102.0M
Stockholders' Equity
NCSM
NCSM
PBYI
PBYI
Q4 25
$126.2M
$130.3M
Q3 25
$110.1M
$115.3M
Q2 25
$106.4M
$104.7M
Q1 25
$103.2M
$97.1M
Q4 24
$98.8M
$92.1M
Q3 24
$96.0M
$71.1M
Q2 24
$91.0M
$48.5M
Q1 24
$93.7M
$51.0M
Total Assets
NCSM
NCSM
PBYI
PBYI
Q4 25
$181.2M
$216.3M
Q3 25
$162.0M
$202.9M
Q2 25
$158.0M
$194.9M
Q1 25
$155.1M
$196.2M
Q4 24
$152.8M
$213.3M
Q3 24
$145.8M
$220.7M
Q2 24
$139.4M
$205.0M
Q1 24
$140.9M
$214.1M
Debt / Equity
NCSM
NCSM
PBYI
PBYI
Q4 25
0.04×
0.17×
Q3 25
0.05×
0.30×
Q2 25
0.05×
0.43×
Q1 25
0.05×
0.58×
Q4 24
0.06×
0.74×
Q3 24
0.07×
1.12×
Q2 24
0.08×
1.87×
Q1 24
0.07×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NCSM
NCSM
PBYI
PBYI
Operating Cash FlowLast quarter
$13.1M
$14.4M
Free Cash FlowOCF − Capex
$12.9M
$14.4M
FCF MarginFCF / Revenue
25.5%
19.1%
Capex IntensityCapex / Revenue
0.4%
0.0%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$21.0M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NCSM
NCSM
PBYI
PBYI
Q4 25
$13.1M
$14.4M
Q3 25
$7.2M
$9.7M
Q2 25
$3.5M
$14.1M
Q1 25
$-1.6M
$3.6M
Q4 24
$10.6M
$15.6M
Q3 24
$-2.0M
$11.0M
Q2 24
$6.0M
$1.0M
Q1 24
$-1.9M
$11.2M
Free Cash Flow
NCSM
NCSM
PBYI
PBYI
Q4 25
$12.9M
$14.4M
Q3 25
$6.9M
$9.7M
Q2 25
$3.2M
$14.1M
Q1 25
$-2.1M
$3.6M
Q4 24
$10.4M
$15.6M
Q3 24
$-2.5M
$11.0M
Q2 24
$5.6M
$1.0M
Q1 24
$-2.2M
FCF Margin
NCSM
NCSM
PBYI
PBYI
Q4 25
25.5%
19.1%
Q3 25
14.9%
17.7%
Q2 25
8.9%
26.8%
Q1 25
-4.2%
7.7%
Q4 24
23.1%
26.4%
Q3 24
-5.6%
13.7%
Q2 24
19.0%
2.1%
Q1 24
-5.0%
Capex Intensity
NCSM
NCSM
PBYI
PBYI
Q4 25
0.4%
0.0%
Q3 25
0.5%
0.0%
Q2 25
0.8%
0.0%
Q1 25
0.9%
0.1%
Q4 24
0.5%
0.0%
Q3 24
1.0%
0.0%
Q2 24
1.1%
0.0%
Q1 24
0.7%
0.0%
Cash Conversion
NCSM
NCSM
PBYI
PBYI
Q4 25
0.88×
Q3 25
1.88×
1.10×
Q2 25
3.81×
2.41×
Q1 25
-0.41×
1.21×
Q4 24
3.07×
Q3 24
-0.49×
0.54×
Q2 24
Q1 24
-0.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NCSM
NCSM

Products$33.8M67%
Services$16.8M33%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons